Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Reduction vs Maintenance of Antipsychotics in Schizophrenia Spectrum Disorder (DREAMS-Phen)
NCT07152184Phase 2Not yet recruiting
- Sponsor
- Strasbourg University Hospital
- Start
- Oct 2026
- Primary completion
- Feb 2032
01
Overview
Phase 2, randomised trial in schizophrenia spectrum and other psychotic disorders (4 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Percentage of patients with functional remission as defined by a Personal and Social Performance Scale score >70 at 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
schizophrenia spectrum and other psychotic disorders
Beyond the preview
Go deeper on NCT07152184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152184.